TRANSCRIPT

Q3 2023 — Prepared remarks

Q3 2023PDF · 12 pages215 KB
1
Philip Morris International Inc.
2023 Third-Quarter Conference Call
October 19, 2023
JAMES BUSHNELL
(SLIDE 1.)
Welcome. Thank you for joining us. Earlier today, we issued a press release containing
detailed information on our 2023 third-quarter results. The press release is available
on our website at www.pmi.com.
(SLIDE 2.)
A glossary of terms, including the definition for smoke-free products as well as
adjustments, other calculations and reconciliations to the most directly comparable
U.S. GAAP measures for non-GAAP financial measures cited in this presentation, and
additional net revenue data are available in Exhibit 99.2 to the company's Form 8-K
dated October 19, 2023, and on our Investor Relations website.
(SLIDE 3.)
Today’s remarks contain forward-looking statements and projections of future results.
I direct your attention to the Forward-Looking and Cautionary Statements disclosure
in today’s presentation and press release for a review of the various factors that could
cause actual results to differ materially from projections or forward-looking statements.
It is now my pleasure to introduce Emmanuel Babeau, our Chief Financial Officer.
Over to you, Emmanuel.

-- 1 of 12 --

2
EMMANUEL BABEAU
(SLIDE 4.)
Thank you, James, and welcome everyone. We delivered very strong and better-than-
expected performance in Q3 driven by IQOS and ZYN. Adjusted diluted EPS grew by
an excellent 20% in currency-neutral terms to reach a record quarterly high of $1.67,
despite a significant adverse currency impact in the period. Once again our total
volumes were positive, with the Q3 progression of over 2% positioning us to deliver
our third straight year of growth.
While not yet in our organic metrics, ZYN continued its exceptional growth with U.S.
volumes up by 66% in Q3 and over 50% year-to-date, with a substantial increase in
category share.
Importantly, our IQOS business delivered another strong quarter with HTU shipments
growing 18%, in line with the year-to-date trend. As covered at our recent Investor
Day, HTU volumes have excellent unit economics relative to cigarettes and the 16.5%
organic net revenue growth from smoke-free products was a key driver in both our
high single-digit organic top-line and double-digit organic OI growth. Smoke-free
products made up over 36% of total net revenues in the quarter, as we drive towards
our new ambition of over two-thirds by 2030, making us substantially smoke-free.
In combustibles, we delivered very robust performance with 6% growth in organic net
revenues, strong pricing and higher category share, despite the impact of adult
smokers moving to smoke-free products.
Our impressive OI growth drove organic year-on-year margin expansion, and a
sequential improvement compared to the second quarter. This includes healthy
expansion in the gross margins of our IQOS business - which surpassed combustibles
in the period - and lower-than-expected commercial costs.
Overall, we are pleased to report another strong quarter and we look forward with
confidence to the remainder of the year and beyond.
(SLIDE 5.)
Turning now to the headline numbers. We surpassed $9 billion in quarterly net
revenues for the first time, as strong positive volumes and continued excellent IQOS
momentum supported organic net revenue growth of 9.3%. This organic growth does
not include the impressive 22% adjusted ex-currency top-line growth of Swedish
Match, led by ZYN.

-- 2 of 12 --

3
Our organic net revenue per unit grew by 7.0%, driven by the increasing proportion of
IQOS HTUs in our sales mix and very firm combustible pricing of 9.0%.
This positive top-line and mix performance drove very strong organic operating income
growth of 11.3% and organic margin expansion of 70 basis points. Again, this excludes
the exceptional performance of Swedish Match, which is included in our adjusted
diluted EPS. We delivered adjusted diluted EPS growth of 20.3%, excluding an
unfavorable currency impact of 17 cents notably due to the Russian ruble and the
balance-sheet-related currency impact in Argentina, as disclosed at our recent
Investor Day. Sequentially lower net financing costs were broadly offset by a higher
tax rate.
(SLIDE 6.)
Our excellent third quarter, combined with a robust H1, resulted in strong delivery year-
to-date. I want to highlight our volume growth of 1.5% and organic net revenue growth
of 7.7%, again reflecting continued dynamic IQOS performance and combustible
pricing. In addition, Swedish Match currency-neutral net revenues increased by 18%
excluding accounting reclassifications.
Year-to-date operating income grew by 2.4% organically, despite accentuated margin
headwinds and a notable OI decline in the first quarter due to the headwinds covered
previously, which are now starting to subside.
Combined with outstanding ZYN performance, this resulted in year-to-date currency-
neutral adjusted diluted EPS growth of 10.7% to $4.65. This is an excellent
performance.
(SLIDE 7.)
Turning now to the full-year outlook. I am pleased to share that following this very
strong year-to-date delivery we are raising our volume, organic sales growth and
currency-neutral adjusted bottom-line growth forecasts.
First to volumes, where we increase our outlook to 1% to 1.5% total shipment growth
for cigarettes and HTUs, despite a lower expectation for the total industry. Within this,
we expect to deliver HTU shipment volumes within the lower half of our prior 125 to
130 billion range. While IQOS fundamentals remain strong, this narrowing reflects a
further delay to the expected market launch in Taiwan, limited underlying growth in
Russia and Ukraine, as well as some uncertainty related to inventory levels in the EU,
as trade partners adjust to the upcoming HTU flavor ban. For combustibles, the

-- 3 of 12 --

4
resilience of our portfolio is reflected in an updated forecast of a 1% to 2% cigarette
volume decline.
ZYN continues to perform exceptionally, with strong adult consumer traction. Following
a further step-up in the U.S. volume run rate, we are now increasing our full-year
nicotine pouch forecast range to 390 to 410 million cans.
Combining the improved volume outlook with robust pricing and continued positive
mix, we are narrowing our organic net revenue growth forecast to around 8%, the
midpoint of our previous range.
As I will come back to shortly, we expect excellent organic OI growth over the second
half of the year. Combining this strong profit performance with the continuation of
ZYN’s phenomenal growth and diligent cost management, allows us to raise our
currency-neutral adjusted diluted EPS growth forecast to 10% to 10.5%. This means
we now expect double-digit growth for the third year running, and translates into a full-
year range of $6.05 to $6.08, including an estimated unfavorable currency impact of
53 cents at prevailing rates.
Last, despite increased currency headwinds we continue to expect operating cash flow
of around $10 billion for the year. This sets us up nicely as we focus on deleveraging
towards our target of around 2 times adjusted net debt to EBITDA in 2026.
(SLIDE 8.)
Now let me provide a different view of our forecasted results. As you can see, 2023
has very much been a year of two halves, with a number of accentuated headwinds
in H1, as explained in prior quarters, including steep cost inflation. H2 is a different
story, and we believe it is more reflective of the underlying trajectory of our business.
First, we expect an accelerated H2 top-line with organic growth of around 9%. Second,
we expect a significant reacceleration in profit growth.
We continue to expect organic OI margin expansion in H2, and we are well on track
after delivering another quarter of sequential adjusted OI margin improvement in Q3,
with margins also expanding organically year-on-year. In H2, we expect strong organic
OI growth of around 10%. For the full year, our expectation remains that organic
margin evolution will be towards the lower end of our -50 to -150 basis point range,
including the expected technical margin impact of around 40 basis points from third-
party arrangements in Indonesia and Ukraine. For Q4, we expect strong OI growth
with broadly stable year-on-year organic margin progression. This includes the

-- 4 of 12 --

5
expectation of higher device sales as we accelerate our ILUMA roll-out to reach around
50 markets by year-end, complimented by further ILUMA device innovation.
This very positive organic OI trajectory in H2 naturally translates into an acceleration
in currency-neutral adjusted diluted EPS growth, bolstered by Swedish Match.
(SLIDE 9.)
Now turning back to our results, our total shipment volumes increased by 2.2% for Q3
and 1.5% year-to-date, putting us comfortably on track to deliver our third sequential
year of growth.
HTU shipment volumes grew by 18% in Q3 to reach 32.5 billion units, driven by
continued strong performance in Europe and Japan. Adjusting for inventory
movements, including the transition back to sea freight, Q3 adjusted IMS grew by
14.4%. This includes Europe at 16% despite heightened competitive activity, notably
in Poland, and a more normalized growth rate in Japan of 12%. Excluding Russia and
Ukraine where growth remains limited, our adjusted IMS advanced by a very robust
16%.
These growth rates exclude the excellent development of oral nicotine, for which
shipment volumes grew by 19% in Q3 and 14% year-to-date on a pro forma basis,
including the U.S. growth of ZYN of 66% and 56%, respectively. If we were to add the
growth of nicotine pouches on a unit basis, our Q3 pro forma smoke-free volumes
grew by 19.5% and our total volumes by 2.5%.
Cigarette volumes declined by a modest 0.5% in Q3, with strong performance in
Turkey and Egypt, and by 1.3% year-to-date, reflecting solid category share
performance in a resilient category, despite robust pricing.
(SLIDE 10.)
I will now walk through the mechanics of our Q3 net revenues. In addition to 2.2%
volume growth, pricing contributed 6.2 points of growth as combustibles remained
strong and the negative impact on HTU pricing of the annualization of excise tax
increases in Japan and Germany notably moderated.
The increasing proportion of HTUs in our business continues to be a consistent top-
line driver, reflecting higher net revenue per unit. The positive mix impact of HTUs,
overall volume growth, and pricing are powerful drivers of our transformation and
growth. We expect ZYN to enhance this further as it starts to be included in our organic
metrics from mid-Q4.

-- 5 of 12 --

6
(SLIDE 11.)
Looking now at adjusted operating income, where the $3.7 billion delivered in Q3 is
also a record high. I am pleased to report that following peak margin headwinds in Q1,
our organic growth has accelerated nicely as inflation, supply chain disruptions and
ILUMA-related factors continue to moderate, and the underlying dynamics of our
transformation bear fruit. The Q3 progression is slightly above our 2024-26 CAGR
target of 8 to 10% organic OI growth and as I covered earlier, we expect our overall
H2 OI growth to be around the top of this range.
(SLIDE 12.)
This strong OI growth, in excess of an already healthy top-line performance, drove a
better-than-expected organic margin expansion of 70 basis points in the quarter. This
was also the first quarter this year where gross margins expanded organically, notably
due to lower shipping costs, ILUMA margin improvement and lower device sales
compared to the prior year. SG&A costs were also organically lower as a percentage
of net revenues, reflecting a good cost performance and some phasing between the
third and fourth quarters.
We delivered a further $120 million in gross cost efficiencies in Q3, now surpassing
our $2 billion target for 2021-23. We aim to continue this run rate, as reflected in our
2024-26 target of an incremental $2 billion in gross savings.
The Q3 margin currency variance includes a 0.6 point impact from the Argentina
balance sheet-related item I mentioned earlier. By its nature, this does not carry
forward to future periods.
(SLIDE 13.)
Now moving to Swedish Match, which is meaningfully accelerating our smoke-free
growth trajectory as we progress towards becoming substantially smoke-free by 2030.
Swedish Match’s business delivered excellent adjusted currency-neutral net revenue
growth of 22% in Q3 and 18% year-to-date. This means that our adjusted pro forma
year-to-date top-line growth was 60 basis points higher at 8.3%. Swedish Match’s
strong profitability also enhanced our year-to-date adjusted OI margin by 70 basis
points.
As we covered at Investor Day, Swedish Match’s smoke-free portfolio has excellent
economics and is already at significant size compared to total PMI, with its product

-- 6 of 12 --

7
contribution – or operating profit before G&A - approaching one quarter of our total
smoke-free business year-to-date.
ZYN remains the key performance driver as it delivered another remarkable U.S.
performance with 66% volume growth, reflecting positive momentum across the
country.
Elsewhere in smoke-free, recent trends of share gains in U.S. moist snuff as well as
category mix headwinds in Scandinavia broadly continued.
We continue to be very pleased with the positive impact of Swedish Match on our
company, and I would like to thank the team for delivering such a great performance.
(SLIDE 14.)
Now let’s examine ZYN’s recent U.S. performance in more detail. Exceptional
progress continued in Q3 with an increase in 12-month rolling shipment volumes
growth of 52% compared to Q3 2022 and 14% sequentially.
Impressively, ZYN Q3 category volume share grew to 70.8%, which is 4.7 points
higher year-on-year and 2.5 points sequentially. Retail value share remains strong at
around 76%, highlighting ZYN’s premium positioning and superior brand equity.
This accelerated growth reflects progressive increases in distribution and a further
broad step-up in nationwide store velocities as the category gains strong traction with
adult nicotine users for its convenience and pleasurable experience.
(SLIDE 15.)
Now focusing on IQOS, starting with user growth. We estimate there were 27.4 million
IQOS users as of September 30th. This represents an increase of 3.7 million users
versus one year ago, and 0.2 million compared to Q2, 2023.
As shown on the right-hand side of this slide, the third quarter of each year typically
experiences slower user growth due to seasonal influences in the calculation. Both
new user registrations and device sales to legal-age smokers continue to advance
strongly, and at levels broadly in line with Q2, when users grew by 1.4 million
sequentially.
Also as in prior years, we expect a substantial acceleration in user growth in the fourth
quarter.

-- 7 of 12 --

8
(SLIDE 16.)
Moving now to IQOS in the Europe Region, where our third quarter HTU share
increased by 1.3 points to 8.6% of total cigarette and HTU industry volume. Continued
share gains include the growing take-up of ILUMA, which is available to over 80% of
IQOS users in the region. In addition to Q3 launches in Denmark and the UK, ILUMA
was launched in Poland, which – like Japan – is a market with high competitive activity.
We look forward to driving its performance here over the coming quarters.
While sequential share is, as usual, optically affected by the seasonality of the
cigarette category, adjusted IMS volumes continue to exhibit robust sequential growth
and reached a record high on a four-quarter moving average. This reflects strong year-
on-year growth of 16% in Q3, despite limited growth in Ukraine. We expect strong IMS
volume growth to continue in Q4, with a corresponding increase in market share.
In the EU, a majority of member states have transposed the Delegated Directive
withdrawing the heated tobacco product exemption from the characterizing flavor ban
into national law. The ban in those markets will be effective as of October 23rd and the
remaining markets are expected to adopt in 2024. As previously mentioned, we are
adjusting our HTU portfolio as required in line with this transposition and while short-
term volatility is possible, including in year-end trade inventories, we do not expect a
significant change in the structural growth of the category.
(SLIDE 17.)
In Japan, IQOS ILUMA celebrated its second anniversary of the national launch in
September and continues to exhibit strong growth due to excellent conversion,
consumer satisfaction, and retention rates.
Adjusted total tobacco share for our HTU brands increased by 3.0 points in Q3 year-
over-year to 26.6%. Importantly, adjusted IMS volumes again grew sequentially on a
four-quarters moving average, reaching over 10 billion units for the first time in Q3'23,
as IQOS outgrew the heat-not-burn category. In addition to this excellent consumer
trend, our Q3 shipments to Japan also benefitted from further switching back to sea
freight during the quarter. This shift is now substantially progressed, and we expect a
more normalized rate of HTU shipments in Q4.
Our premium-priced TEREA HTUs and mainstream priced SENTIA HTUs continued
to grow individually and in aggregate, reaching Q3 offtake shares of around 18% and
8% respectively, despite the impact of seasonality. Our Japan city shares also continue
to progress with a number reaching over 30%. We continue to see a long runway of
growth in Japan over the coming quarters.

-- 8 of 12 --

9
(SLIDE 18.)
In addition to strong IQOS gains in developed countries, we continue to see very
promising growth in Low and Middle-Income markets.
This slide highlights a selection of Q3 key city offtake shares across markets in Eastern
Europe, Africa, Asia, and Latin America. We see notable ongoing success in Egypt
with Cairo offtake share up 3.5 points to almost 9%, and in Santo Domingo as our
leading Latin American city, with offtake share around 8%. Most promising is the 3.1%
offtake share in Urban Jakarta, where IQOS is only available via the IQOS Club
members program. We continue to see robust offtake volume growth across these
important future markets, despite seasonal effects on sequential share metrics.
(SLIDE 19.)
I’d like to spend a moment now on combustibles, where our portfolio delivered strong
organic net revenue growth of 6.2% in Q3 and 5.6% year-to-date. This reflects another
strong quarter of pricing, with notable contributions from Germany and Indonesia. With
better-than-expected pricing in Q3 of 9.0% and 8.6% year-to-date, we now forecast a
full-year increase of 8% to 8.5%.
Our cigarette category share grew by 0.6 points in Q3 and 0.3 points year-to-date.
This reflects notable contributions from Egypt, Poland, and Turkey, resulting in only
modest volume declines. Our leadership in combustibles helps to maximize switching
to smoke-free products and we have fully achieved our ongoing objective of stable
category share over the last 2 years, despite the impact of IQOS cannibalization.
(SLIDE 20.)
This combustible share performance, combined with the structural growth of IQOS,
supports robust overall market share gains. We captured 0.9 points of international
cigarette and HTU share in Q3, and 0.7 points year-to-date.
As covered at Investor Day, our superior share of smoke-free products gives us a
formidable platform for sustainable market share gains, with superior unit economics.
(SLIDE 21.)
Now, let me update you briefly on our exciting innovation and expansion activities,
which will be critical as we aim to reach over two-thirds smoke-free net revenues by
2030, including 60 markets over 50% and 40 markets over 75%.

-- 9 of 12 --

10
As we covered at Investor Day, the global roll-out of IQOS ILUMA continues. We
launched ILUMA in 4 markets in Q3, reaching 27 markets in total, which represent
around 75% of our IQOS business by volume. ILUMA continues to generate excellent
growth, with upgrades from existing users and new user acquisition. With a further 6
markets launched already this month we expect ILUMA to be present in around 50
markets by year-end and to essentially complete the roll-out next year.
As also mentioned during Investor Day, superior tobacco taste is critical to our ongoing
success, and we are further exploring complex and new taste spaces to enhance our
tobacco flavor experience. On the other end of the consumer preference spectrum,
we will be offering zero tobacco consumables for non-tobacco flavor discovery under
the LEVIA brand. Just as nicotine pouches are an evolution from snus to make the
oral category relevant to more adult smokers, LEVIA is a similar non-tobacco evolution
for IQOS as we broaden our offering to increase switching away from combustibles.
The U.S. represents the most significant opportunity to drive accelerated smoke-free
growth at both the top- and bottom-line. We are continuing to invest behind ZYN and
readying our organizational and commercial capabilities for the launch of IQOS in Q2
2024 and a scaled-up roll-out with ILUMA once authorized. We remain on track to file
for IQOS ILUMA’s PMTA and MRTPA this month.
The international expansion of nicotine pouches remains a key mid- to long-term
focus, notably for ZYN as the world’s leading brand. During the third quarter we re-
launched ZYN in Switzerland and, following positive regulatory developments, rolled-
out ZYN in Finland.
(SLIDE 22.)
Moving now to sustainability. Addressing the product health impact of combustible
products by switching adult smokers to smoke-free products, which are designed and
marketed for adult use, remains our most critical priority. This transformation is at the
core of our strategy as we become a more sustainable business with accelerated
growth and returns over time.
With regard to tackling climate change, I am delighted to report that the Science Based
Targets initiative validated our Forest, Land, and Agriculture emissions reductions
targets, a recognition achieved by very few companies. We pledged to reduce these
absolute scope 3 emissions by 33% by 2030, which is significant given that scope 3
remains the most challenging aspect of any company’s decarbonization strategy.

-- 10 of 12 --

11
In September, almost 20,000 employees in over 60 countries participated in World
Clean-up Day, showcasing our commitment to raising awareness around littering, as
part of our wider strategy to reduce post-consumer waste.
We have long expressed our support for more rigor in sustainability-related reporting
and welcome recent moves towards greater consistency in standards under strong
governance frameworks. As part of our ongoing work, we provided responses to
consultation requests from the International Sustainability Standards Board to help
shape the development of their work plan and updates to the SASB standards. PMI
continues to be recognized by organizations such as the World Business Council for
Sustainable Development as a leader in non-financial reporting.
We have much more to share on our sustainability efforts and transformation. Jacek
will be presenting at the CECP CEO Investor Forum in New York on November 14,
and the event is open to all those who would like to attend.
(SLIDE 23.)
To conclude today’s presentation, we continue to deliver sustainable growth through
our transformation. The powerful trajectory of our smoke-free business gives us
confidence in strong full-year results built on volume growth, positive mix, pricing and
cost management. Considering the headwinds faced, notably in the first part of the
year, we believe this speaks strongly to the fundamentals of our growth model.
Notably, the outstanding performance of IQOS and ZYN continues, further enhancing
our position as the global smoke-free champion. We have exciting plans to accelerate
our smoke-free future in both the U.S., the largest smoke-free market, and
internationally.
We are confident in our 2024-26 CAGR targets of 6% to 8% organic top-line growth,
8% to 10% organic OI growth and 9% to 11% currency-neutral adjusted EPS growth.
We also have a clear guiding objective with our new ambition to be substantially
smoke-free by net revenues in 2030, as another key milestone on our journey towards
a smoke-free future.
And finally, with our latest dividend raise in September, we have delivered 16 years of
continuous dividend increases since our 2008 spin, despite the ups and downs of
economic and currency cycles. This translates to a cumulative 183% increase and
CAGR of 7.2% since 2008, with an annualized dividend of $5.20. As this
demonstrates, our commitment to shareholder returns through a progressive dividend
remains steadfast.

-- 11 of 12 --

12
(SLIDE 24.)
Thank you. We are now happy to answer your questions.
JAMES BUSHNELL
(SLIDE 25.)
That concludes our call today. Thank you again for joining us. If you have any follow-
up questions, please contact the Investor Relations team. Thank you again and have
a nice day.

-- 12 of 12 --